United States: Protecting Wearable Technology – Patent Searching With The Lens – IP News On Monsanto And Apple – IP Fridays Episode 9

Last Updated: September 1 2014
Article by Rolf Claessen and Kenneth Suzan

In this episode we interview Kevin Nickels, COO of Preventice, about protecting wearable technology. We also have the latest news about Monsanto`s dual threats of IP theft, cool new features coming up in Apple products and a very helpful tool for searching patents – The Lens.

Podcast: Play in new window | Download (Duration: 28:56 — 16.8MB)

Please leave your comment below!

IP FRIDAYS

Co-Presenters:

Rolf Claessen and Kenneth Suzan

Episode 9 – August 22, 2014

RC = Rolf Claessen

KS = Kenneth Suzan

KN = Kevin Nickels, COO of Preventice

Hi. This is Jeanine Percival Wright, the Director of Legal Affairs for Intellectual Property and Litigation with True Religion Brand Jeans in beautiful Los Angeles, California. You are listening to IP Fridays. Thanks for the great podcast guys.

KS: Hello and welcome to this episode of IP Fridays. Our names are Ken Suzan and Rolf Claessen and this is THE podcast dedicated to intellectual property. It does not matter where you are from, in-house or private practice, novice or expert, we will help you stay up-to-date with current topics in the fields of trademarks, patents, design and copyright, discover useful tools and much more.

RC: Today we have the latest news on Monsanto and Apple. Ken is interviewing Kevin Nickels who is the COO of Preventice and they will talk about wearable technology, and also we will tell you about a very cool tool for patent searching which I frequently use and, in fact, I will tell you about this tool right now.

The Lens at www.lens.org, the link is in the show notes, is a patent search tool that I frequently use for prior art search. Many jurisdictions are covered by this database and you can build really complicated queries with the advanced search and one really interesting feature is that you cannot only search patent applications and granted patents, but you can also search search reports, you can search supplementary protection certificates, you can search plant patents, you can search design rights and some really cool other document types so you might cover even more prior art than with some paid search tools. You can search the full text or you can search inventors or owners, the title, abstract claims, or you can search applicants or you can search also by publication number or filing number, and you can also search classifications. So, it seems to be really powerful.

One thing that I didn't find is the coverage of the databases and especially what kinds of countries are covered in full text and what kind of legislations are not covered in full text so I would not really use this tool for, for example FTO searches (freedom to operate searches), but for prior art it has given me a really, really helpful result. Typically, I use Total Patent by LexisNexis, but this tool, The Lens, has been complimentary for a while now and it has given me some different prior art documents that I didn't find with Total Patent. So, go over to www.lens.org and try it out yourself.

Next, let's head over to Ken and Kevin Nickels — they are discussing how wearable technology is changing the lives of many.

KEN SUZAN'S INTERVIEW WITH KEVIN NICKELS, COO OF PREVENTICE

KS: Thank you Rolf. I am joined today by Mr. Kevin Nickels who is the COO of Preventice. Preventice is a privately owned company and leading developer of mobile health applications and remote monitoring systems that connect mobile home-based and on-premises technologies to deliver continuous patient care across the health continuum. Welcome, Kevin, to our program.

KN: Good morning Ken. Thanks for inviting me.

KS: Yes, I am so glad you are able to join us. There are lots of interesting things I want to talk to you today about. Could you tell me a little bit about your experience and your background so our listeners can get an idea of the forty years of experience that you have.

KN: When you say it that way, it makes me feel a little old. I am a serial entrepreneur. I have technical roots. I have been in the healthcare field for not quite all forty years but had an interesting departure at one point in time into aerospace, came back into healthcare, done a number of startups, been in multiple clinical areas all the way from nephrology to cardiovascular, became interested in online behavior modification about 10-15 years ago, actually applied and received a patent on the topic, and have become a student of adherence to care plans over that decade period of time because I see a lot of the reasons for healthcare costs rising and staying high is tied to the fact that physicians frequently prescribe things and patients don't always adhere to them. So, when the CEO, Jon Otterstatter, from Preventice approached me about joining him in building Preventice, I was excited at the opportunity because here I was a med-tech guy and had done a number of things in the medical device area but never have had a chance to take a swing at an IT arena as well as being able to actually do something that would perhaps be able to attenuate healthcare costs.

KS: Sure, and you have been with Preventice how long?

KN: Not quite a year. The company is about 5 years old. The company grew itself largely out of a group of IT folks out of Rochester, pulling software people out of IBM as IBM was repositioning and then licensing some cardiac monitoring technology from Mayo Clinic.

KS: And that would be the BodyGuardian® Remote Monitoring System?

KN: It is.

KS: What is that exactly?

KN: Yeah, it's actually a fairly broad offering. The vision of the company I think early on started out looking at remote patient care or monitoring. We should be careful because monitoring is the passive monitoring used in a software platform with wearable technology. Remote patient care I think is where we are going from the standpoint of more active interventions. But most tactically, the company developed a low body burden ECG cardiac monitoring device. If you think about a halter monitor, I think a lot of people have worn those for telemetry for 12 to 24 to 36 hours of cardiac monitoring, this technology enables a patient to be monitored for cardiac arrhythmias for the better part of 30, 60, sometimes 90 days. So the cardiac application is the first clinical physiologic measurement but the company has built upon the software platform that obviously includes an Android phone and the server and then down into a portal for monitoring but it also includes things like blood pressure, weight scale, actively working on integration of glucometers, coagulometers, and Pulse Ox. So, it's a fascinating platform. It's a fascinating time to be in healthcare IT.

KS: What do you think about the growing prevalence of wearable technology? Now, it's everywhere. We are hearing about it, we are seeing things in the media. Is this a fad that we are dealing with?

KN: Yes, that is a great question because you know my thoughts in preparing for this interview took me down two paths. One is that there is clearly a lot of froth and a lot of interest about things that are cool. More of the gadgetry, you know the fun glasses, the Fitbit® [device], you know, things like that. I think these are the things and a lot of people, frankly the younger generation, are excited about because they are things that they can talk to each other about it at a health club or what have you and that one I think is generating a lot of the noise in the market because it is quick to market. It's a great opportunity and it is measured in the B numbers. It is a large market and we talk a little bit about how fast those product life cycles are but the reality is that I think a lot of the opportunity to really have an impact on health care is, if you will, at a little bit of a different end of the marketplace and that one is where technology has had to go through more regulatory shakedown. You're basically trying to get a patient engaged but you are also trying to get a physician to prescribe and then obviously in today's world and the U.S. healthcare system you have to get a payor to pay for it. So, there is a continuum and I just described two book ends...the consumer side, as well as the healthcare more classic fee for service. I think the inroads of where the wearable technology is going to arise is where it can actually impact healthcare by improving clinical outcomes reducing costs by enabling physicians to manage more patients away from the most expensive side of healthcare which is the hospital. So, that is the area that I have been the most interested in but it's not to distract from a huge opportunity on the consumer side.

KS: Sure. Do you see any differences from where we were, let's say in the late 1990's, early 2000's when there was basically an explosion of Web development and everyone was running to the Web? Is that the same thing here with wearable technology?

KN: I think there is. I mean, we as a country tend to like to run at large moving trends you know where you can put money to work and you can create a lot of excitement. I think in this particular case, it is an interesting natural build because micro machine sensors actually started, I was involved in buying a pressure micro machine pressure sensor business in the very early 90's and so the reality is that micro machine pressure sensors and things like that have been evolving rather rapidly over the last two decades, I think really what you have seen is the convergence of a lot of software people that can do some pretty exciting things algorithmically with micro sized small accelerometers and other kinds of sensors that can allow, if you will, more data to be pulled off of the body and effectively converted into clinically valid or consumer interested physiologic measurements. So I think it is a natural evolution – much like the Internet. I think that to leverage it as much as the potential that it offers – its promise if you will, I do believe it does need to have some clinical value and not just a consumer spin because I think those are going to be very fast and furious and we'll talk about IP shortly I'm sure but you know it sets up a very interesting discussion of what you do as far as having two very distinct markets.

KS: You have been with startup companies over many decades. If you were to talk to a startup company today, what would be some of the things you would tell them before they jump into the wearable space? What do they need to know before getting into something like this?

KN: Well, you know, I was touching a little bit just now. Because this is a continuum, it makes building a company very easily become confusing and when you are out raising capital, you know as you are going from Investor A to Investor Z, you will find yourself being tested because some of them will come from a strong consumer perspective and others will come from a strong healthcare perspective let's say and so I think probably the biggest nugget there is — really try to identify where you want to pursue and try to maintain conviction on it and that means you have to have it thought through. It means you have to sit down and think through what's it going to take for you to actually take a great idea and get it into the consumer market and, unfortunately, the healthcare system does have a lot of regulatory hurdles to get through, but it generally has a much larger sustainable terminal value than something that is more quick hit and then that starts to impact how you raise capital.

KS: Sure. With respect to intellectual property, the name of our podcast is IP Fridays, IP is very important to many companies. Can you tell me about the importance of IP in the wearable space? What do companies need to do before getting involved with wearables and how important is that asset to the company?

KN: Yeah, I think it is going to become even more important. You know, when markets start to become frothy, and start to grow the interest of a lot of investors, value starts to be assessed by intellectual property portfolios. I think frequently it is an afterthought. And filing patents is not an inexpensive activity. There have also been a lot of changes in intellectual property law. I would expand the discussion to include trademarks and brands, I might add.

KS: Yes, very important in what we do every day.

KN: Yeah, and so I think it goes back with having the end in mind and how you actually want to create, if you will, an exit and who would be potentially the exit partners and what would basically move their financial needle as to pay you a higher price for the asset that you are effectively building and I think IP, in that broad definition, is clearly a component of it. I think the consumer business is going to tend to be much more brand and trademark sensitive because you are going to have to deal with quicker S curves. The longer term ones are going to be powerfully important to have: technology, device, software, algorithms, and predictive analytic kind of IP protection because you are going to have to go through a much longer journey to get the product through all of the regulatory lifecycles. So it goes back to start with the end in mind — what market are you going to go after and then that is going to drive a lot of your investment dollars as you are building the company.

KS: Sure. Now, as the COO, I'm sure there a lot of issues that you deal with on a day-to-day basis. What are some of the pressing things that keep you up at night or that you are constantly thinking about or that you are grappling with? Particularly as we are talking about the wearable area and that sort of space?

KN: Well, you know, it is multifaceted. But I do believe that one of the most important assets that a company has is people and clearly this topic that we talked about earlier Ken is extremely frothy, very active, and I don't think it's going to be a fad so that means that hiring people that can solve problems today and actually can grow and solve tomorrow's problems if not next year's problem is one that keeps me awake at night a lot. Where do you find those kinds of people? That's point one. Point two as it links to people is that what kind of regulatory or commercial trends are going to be hitting us? You know, in the case of Preventice, we have chosen a very healthcare strong strategy. We have spent a lot of time establishing clinical evidence and what have you, and what we are becoming more sensitive to is that in addition to the FDA compliance area, which is no small area relative to software development I might add, you also have huge issues and challenges associated with privacy and security. It is an area in which I think Preventice has done an outstanding job very early on. But the reality is that managing data is incredibly challenging. You know, you can basically say you can anonymize it but when you are actually monitoring key physiologic components, you are going to have questions that pop up, you are going to have to interrogate data, and in some cases you are going to have to actually have more clarity as to what kind of patient trends just to be able to handle the FDA issues, that then tees up the ONC issues which is a privacy regulatory body, and, of course, you are playing with telecommunications so you have the FCC. There are a lot of pieces in this market that people don't fully grasp.

KS: Wow. Very interesting. Speaking of pieces, one of these pieces is actually the mobile piece which I think is a critical part on these wearable technology devices. Curious what type of mobile platform you use. I know you brought in a Smartphone today. Have you looked at wearable technology for yourself too?

KN: Well the answer is that I am still relatively healthy and have been for forty years, so my level of technology probably revolves around a pedometer and an app on my phone to see what kind of food I am consuming.

KS: Do you use that every day?

KN: I don't. But I try to use it once a week. I think the reality is that the government, the FDA, is also trying sort through, as you are hearing about Apple and Samsung and the equivalent, and you are trying to figure out how to have powerful apps on a phone and then give the FDA, FCC and ONC the comfort that these apps are not going to get corrupted and basically cause other issues to flow out. So in the case of the Preventice solution right now we are using a lock down dedicated Android phone for the application. We get a lot of people that complain about the fact that they have to carry two phones. We did that on purpose. I think that as the FDA becomes more understanding and appreciative of certain kinds of controls that we can put in place, you can see our application evolve quickly into a phone app that would be just part of your phone. I think the reality is that Smartphones have the ability to handle these kind of technologies easier than an old flip phone if you will. But I would even argue that in some cases, you are dealing with, bump it up if you will, with remote patient monitoring which is where we are going with areas within the geographical areas of the country that just don't have enough Internet access and you are hearing politicians talk about it that really the U.S. market really does not have as robust of a cellular system to really provide continuous monitoring. So that provides us some issues. So, where does that all lead you? Well, you start looking for Wi-Fi hubs, you are looking for other ways of communicating key information. Again, this goes back to where is your market focus. If you are dealing with a Fitbit® [device], we are only worrying about things that are maybe when you are active, at a health club or when you are exerting something like riding bike or whatever. You are not interested in continuous monitoring. In my case, if I am monitoring somebody for cardiac arrhythmias, being down for a couple hours is not a good thing.

KS: That's right. And it is critical to have that access.

KN: And it becomes very use case driven. And I would argue that the more compelling use cases are going to have the higher value but I think this is all part of positioning focus and what have you.

KS: You know, I think about health insurance companies. Do you think that health insurance companies will take an active interest, if they haven't already done so, in wearable technology in a way to help keep their subscribers fit and healthy?

KN: They are clearly moving in these different directions. I don't believe I know of any payor, whether it is government or private, that is not looking at this area. They are all scratching their heads trying to figure out what the value proposition is for them. That could be a clichéous kind of comment but the reality is that this kind of data and the conversion of the information is effectively longitudinal in nature. What you are doing is trying to see if you can actually change somebody's behavior. You were just asking me how often do I wear my pedometer and update the thing. That is an example of the kind of key questions that the payors are interested in because if they pay to have something done for 30 days, with the anticipation that you are going to continue it for the rest of your life, and you don't, then that is a lost investment in their world and we see that with regard to pharmaceuticals. So what I see right now is a lot of interest, a lot of questions, and they are looking for companies that have got the investors that can basically support the company through a journey of proving clinically and economically the value proposition.

KS: Excellent. Two final questions: Do you think that wearable technology is totally dependent on the success of mobile phones, for example, or will there be other technologies that drive that success?

KN: Yeah, I think that I am already aware of a couple of the large communications companies that are trying to figure out how to make the technology smaller, lighter, and easier. You know, lapels. I mean, look at the things that Samsung is doing which is exciting. Apple is doing the same thing. I think at the end of the day, it is going to evolve fairly quickly. I think it is going to evolve as quickly as the regulatory, if you go down that pathway, will tolerate it. I think the engineers have the ability to drive it. I think it becomes an issue of the channel as well as what the regulators can tolerate and approve and accept. I think you are seeing a lot of activity with Samsung and Apple these days with the FDA trying to educate and help them move down the road so I think stay tuned on that one.

KS: Yeah. I've seen a number of trademark applications being filed by Apple recently in connection with their HealthKit.

KN: I think it is a very frothy area. I think, not to keep going back to a regulated area, but if you want to pursue something that is going to have a longer term sustainable model, even though you have to make that system move faster, I think you do find yourself looking at basically a lot of upstream education.

KS: Excellent. Any sage advice or any words of wisdom, I know we talked about a lot of things — that you could impart to our listeners wherever they are around the world?

KN: You know, I said it a little while ago, it's always about people. It's about clarity of where it is you are trying to g– and trying to find access to finding capital that can actually help you get all the way through the journey, probably times two. It always takes more time and money than anybody wants to believe. I think it is an extremely exciting time. I think the amount of people that are excited to hear the company's stories are wildly high. I think everybody is interested in seeing this kind of technology brought forward so I think it is an exciting time, finding good people, finding people that can grow with the company is always key in patient investors.

KS: Kevin, this has been so fascinating. Thank you so much for joining us today.

KN: Appreciate it. Thank you very much, Ken, for the opportunity.

KS: Thank you.

KN: Good bye.

RC: If you want to know more about Kevin, please go to www.ipfridays.com/kevin.

In the beginning I promised to tell you more about Monsanto and Apple. Well, there was a recent article on the CBS Website about Monsanto facing a threat after intellectual property theft. They are actually fighting against two different kinds of opponents. One kind of opponent is competitors in China who are trying to steal the latest research of Monsanto because developing their own technology would be more expensive than stealing the technology and, on the other hand, they are facing intellectual property theft by critics who want to expose the latest research of Monsanto in order to generate negative press. Both is not very helpful and I think that many companies struggle with these kinds of intellectual property theft. If you want to know more about this, head over to www.ipfridays.com/monsanto.

There is another interesting story I want to share with you. On the famous blog Patently Apple, there was a recent story about Apple patents covering touch screens for Apple Mac and a new way to define tasks while working on a document, called Atomic Tasks, and then there is a new gesture to invoke Siri on the desktop. So it seems to be clear from the patent applications that were published that touch screens are coming to Apple Mac and they will have really cool functionality like calling for the help of Siri by just drawing a double circle on the desktop and then there is another really cool feature where when you are working on a document and you want to find a suitable image that you can include into the document, for example, you can give the operating system a task like an Atomic Task to search for a particular image based on, for example, keywords and then after awhile you return to this Atomic Task and then you just select the image or choice of images that you want to include into your document. If you want to read the full article at Patently Apple, please go over www.ipfridays.com/patentlyapple.

KS: That's it for this episode.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.